SCHEMBL4905151

SCHEMBL4905151

Cc1ccc(Cn2c(-c3ccc(Oc4ccc5[nH]c(C(=O)O)cc5c4)cc3)cc(C(F)(F)F)cc2=O)c(C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
PIN1 Q13526 1/20 0.41
XDH P47989 1/20 0.38
FLT3 P36888 3/20 0.37
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
SRD5A2 P31213 1/20 0.36
DDR1 Q08345 1/20 0.34
RHEB Q15382 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PPARG P37231 2/20 0.34
PPARD Q03181 2/20 0.34
PPARA Q07869 2/20 0.34
GAA P10253 1/20 0.33
RXRA P19793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4899609 0.92 KDM4E (0.46) KMT2AXDHKDM4EALDH1A1HPGD
SCHEMBL4905520 0.86 PDGFRB (0.38) XDHFLT3KDM4EALDH1A1HPGD
SCHEMBL4897578 0.84 RXRA (0.53) KMT2APIN1XDHFLT3KDM4E
SCHEMBL4904808 0.80 KDM4E (0.44) KMT2AXDHKDM4EALDH1A1HPGD
SCHEMBL4904765 0.76 RXRA (0.49) KMT2AXDHFLT3KDM4EALDH1A1
SCHEMBL2387472 0.76 RXRA (0.49) KMT2AXDHKDM4EALDH1A1HPGD
SCHEMBL4902430 0.76 KDM4E (0.43) KMT2AXDHKDM4EALDH1A1HPGD
SCHEMBL4897266 0.76 RXRA (0.49) KMT2AXDHKDM4EALDH1A1HPGD
SCHEMBL4907552 0.75 RXRA (0.48) KMT2AXDHFLT3KDM4EALDH1A1
SCHEMBL4904411 0.75 RXRA (0.48) KMT2AXDHFLT3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US claimed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO claimed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO claimed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO disclosed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 KMT2A 2364/4885PIN1 4361/4885XDH 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.